← Eichor
Study identifier: NCT07309289 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer (CRC)  ·  Sponsor: Shanghai Zhongshan Hospital

PhasePhase 3
Planned participants144
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To explore the safety and efficacy of NALIRIFOX plus targeted therapy versus FOLFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Tianshu Liu, Doctor  ·  +86-21-64041990  ·  liu.tianshu@zs-hospital.sh.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Zhongshan HospitalShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07309289